GlassScriptPhysician profile
Enerolisa Paredes
NPI 1841890712
$2,296.59
in general payments reported to CMS, 2019-2025
15 companies · $950 in 2025
The $950 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $250 · 2023: $471 · 2024: $390 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $859.47 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $427.76 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $197.32 | 2023-2024 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Glaxosmithkline, LLC. | $187.40 | 2021-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $132.03 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.47 | 2025 | Reblozyl |
| Genzyme Corporation | $63.86 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.59 | 2022-2023 | Jardiance |
| Ani Pharmaceuticals, INC. | $54.88 | 2025 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $49.49 | 2025 | Recorlev |
| Amgen INC. | $31.60 | 2025 | Repatha |
| Verona Pharma, INC. | $30.56 | 2025 | Ohtuvayre |
| Springworks Therapeutics, INC. | $27.69 | 2025 | Gomekli |
| Electromed, INC. | $25.79 | 2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $24.68 | 2024 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enerolisa Paredes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.